Biosimilars Deals 2020 Archives | Page 2 of 6

Celltrion enters deal to acquire Takeda Pharmaceuticals Primary Care businesses

Jun 11, 2020

Celltrion announces a $278 million deal to acquire Takeda Pharmaceuticals Primary Care businesses in the Asia Pacific. Under the agreement, Celltrion will gain access to patent, trademark and marketing rights for 18 prescription and over-the-counter brands in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Singapore and Australia.

Celltrion announces deal to acquire Takeda Pharmaceuticals Primary Care businesses

Jun 11, 2020

Celltrion announced a $278 million deal to acquire Takeda Pharmaceuticals Primary Care businesses in the Asia Pacific. Under the agreement, Celltrion will gain access to patent, trademark and marketing rights for 18 prescription and over-the-counter brands in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Singapore and Australia.

Xbrane Pharma announces agreement with Akademiska Hus for lease of premises

Jun 8, 2020

Xbrane Pharma announced that it has entered into an agreement with Akademiska Hus for the lease of new premises at Campus Solna. From March 2021, Xbrane will establish a new development lab for biosimilars and will move their headquarters to the new campus at Solna. Xbrane has said that the new development lab will give them expanded capacity and the ability to start development of additional biosimilar candidates.

Aurobindo Pharma announces willingness to sell biosimilars businesses to subsidiary

Jun 3, 2020

LiveMint reported that Aurobindo Pharma announced it would sell its biosimilars business to its wholly owned subsidiary, CuraTeQ Biologics in 2019/20 Q4 earnings call.

AbbVie completes acquisition of Allergan

May 8, 2020

AbbVie announces it has completed its acquisition of Allergan, following regulatory approval from all relevant Government agencies. AbbVie will now have access to Allergan’s neuroscience products including Vraylar® and Ubrelvy®, and aesthetic products including the Botox® and Juvederm® brands.

Bausch + Lomb enter exclusive licensing agreement with STADA and Xbrane Biopharma

May 6, 2020

Bausch + Lomb announced it has entered into an exclusive licensing agreement with STADA and Xbrane Biopharma for the development and commercialisation of a ranibizumab biosimilar. Under the agreement, Xbrane and STADA will be jointly responsible for finalising development of the biosimilar, with Xbrane to provide commercial supply and Bausch + Lomb responsible for sales, marketing and all other commercialisation efforts.